soul semaglutide (Semaglutide cardiOvascular oUtcomes triaL) in individuals with Oral GLP-1 receptor agonist Rybelsus

Teichgraeber, D

Published studies suggest the magnitude of effect in obesity cohorts may be larger with triple agonism at top doses, though head-to-head laboratory comparisons are still emerging in the published record

Since the IRA gives biologics a 12-year safe harbor from negotiations, which aligns with the biologic exclusivity provided by the Biologic Price Competition and Innovation Act, it creates a scenario in which the innovator could be facing negotiations just as its first biosimilar competition prepares to launch

Hims & Hers do not display media logos on their weight loss pages

Inflammation modulation GLP-1 medications also reduce systemic inflammation, which is a key driver of many chronic diseases

Diabetes Care 2005;28:850-5.PubMed 28